A phase 1, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian subjects
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs CSL 112 (Primary)
- Indications Atherosclerosis; Myocardial infarction
- Focus Pharmacokinetics
- Sponsors CSL
- 22 Nov 2018 Status changed from recruiting to completed.
- 04 Jun 2018 Status changed from not yet recruiting to recruiting.
- 14 May 2018 New trial record